

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

<sup>Pr</sup>**M-DORZOLAMIDE-TIMOLOL**

Dorzolamide and Timolol Eye Drops, BP

Solution, 20 mg/mL dorzolamide hydrochloride and 5 mg/mL timolol maleate, Ophthalmic

BP

Elevated Intraocular Pressure Therapy

Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic Blocking Agent

Mantra Pharma Inc.  
9150 Leduc Blvd., Suite 201  
Brossard, Quebec  
J4Y 0E3

Date of Initial Authorization:  
MAY 09, 2023

Submission Control Number: 273754

## RECENT MAJOR LABEL CHANGES

Not applicable.

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>RECENT MAJOR LABEL CHANGES</b> .....	<b>2</b>
<b>TABLE OF CONTENTS</b> .....	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION</b> .....	<b>4</b>
<b>1 INDICATIONS</b> .....	<b>4</b>
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
<b>2 CONTRAINDICATIONS</b> .....	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION</b> .....	<b>5</b>
4.1 Dosing Considerations .....	5
4.2 Recommended Dose and Dosage Adjustment .....	5
4.4 Administration .....	5
4.5 Missed Dose .....	5
<b>5 OVERDOSAGE</b> .....	<b>5</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING</b> .....	<b>7</b>
<b>7 WARNINGS AND PRECAUTIONS</b> .....	<b>7</b>
7.1 Special Populations .....	10
7.1.1 Pregnant Women.....	10
7.1.2 Breast-feeding .....	11
7.1.3 Pediatrics .....	11
7.1.4 Geriatrics.....	11
<b>8 ADVERSE REACTIONS</b> .....	<b>11</b>
8.1 Adverse Reaction Overview .....	11
8.2 Clinical Trial Adverse Reactions .....	12
8.5 Post-Market Adverse Reactions.....	12
<b>9 DRUG INTERACTIONS</b> .....	<b>13</b>

9.2	Drug Interactions Overview .....	13
9.4	Drug-Drug Interactions .....	13
9.5	Drug-Food Interactions .....	14
9.6	Drug-Herb Interactions .....	14
9.7	Drug-Laboratory Test Interactions.....	14
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>14</b>
10.1	Mechanism of Action .....	14
10.3	Pharmacokinetics .....	14
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>16</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS .....</b>	<b>16</b>
	<b>PART II: SCIENTIFIC INFORMATION.....</b>	<b>17</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION .....</b>	<b>17</b>
<b>14</b>	<b>CLINICAL TRIALS.....</b>	<b>18</b>
14.1	Clinical Trials by Indication .....	18
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>23</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>23</b>
<b>17</b>	<b>SUPPORTING PRODUCT MONOGRAPHS .....</b>	<b>27</b>
	<b>PATIENT MEDICATION INFORMATION.....</b>	<b>28</b>

## **PART I: HEALTH PROFESSIONAL INFORMATION**

### **1 INDICATIONS**

M-DORZOLAMIDE-TIMOLOL (dorzolamide and timolol) is indicated in the treatment of elevated intraocular pressure (IOP) in patients with:

- ocular hypertension
- open-angle glaucoma

when concomitant therapy is appropriate.

#### **1.1 Pediatrics**

Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized.

#### **1.2 Geriatrics**

Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see [7.1.4 Geriatrics](#)).

### **2 CONTRAINDICATIONS**

Dorzolamide hydrochloride and timolol maleate is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- Patients with reactive airway disease, bronchospasm, including bronchial asthma or a history of bronchial asthma, or chronic obstructive pulmonary disease.
- Patients with sinus bradycardia, sino-atrial block, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock.
- Patients with severe renal impairment ( $\text{CrCl} < 0.5 \text{ mL/s}$ ), as dorzolamide hydrochloride and its metabolite are excreted predominantly by the kidney. M-DORZOLAMIDE-TIMOLOL has not been studied in these patients and is not recommended.
- Patients taking an oral carbonic anhydrase inhibitor, as there is potential for an additive effect with the known systemic effects of carbonic anhydrase inhibition. The concomitant administration of dorzolamide hydrochloride and timolol maleate and oral carbonic anhydrase inhibitors has not been studied and is not recommended.

## 4 DOSAGE AND ADMINISTRATION

### 4.1 Dosing Considerations

- When substituting M-DORZOLAMIDE-TIMOLOL for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start M-DORZOLAMIDE-TIMOLOL on the following day.
- If another topical ophthalmic agent is being used, M-DORZOLAMIDE-TIMOLOL and the other agent should be administered at least ten minutes apart.

### 4.2 Recommended Dose and Dosage Adjustment

- Adults ( $\geq 18$  years of age): The dose is one drop of M-DORZOLAMIDE-TIMOLOL (dorzolamide and timolol) in the affected eye(s) two times daily. A comparative clinical trial of 3 months duration has been performed with M-DORZOLAMIDE-TIMOLOL in adult patients. The results have indicated that the efficacy and safety profile of these two formulations appear to be equivalent. No studies were conducted in special populations (pediatric, kidney or liver diseases, etc.). For details please also refer to the [14 CLINICAL TRIALS](#) section.

When substituting M-DORZOLAMIDE-TIMOLOL for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start M-DORZOLAMIDE-TIMOLOL on the following day.

- Pediatrics (<18 years of age): Health Canada has not authorized an indication for pediatric use (see [1.1 Pediatrics](#)).

### 4.4 Administration

**Do not allow the pipette to touch the eye or areas around the eye.**

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity.

If the patient has difficulty administering M-DORZOLAMIDE-TIMOLOL eye drops, the assistance of a family member or caregiver may be needed.

### 4.5 Missed Dose

If a dose is missed, it should be applied as soon as possible. However, if it is almost time for the next dose, the missed dose should be skipped and the next dose should be taken as usual.

## 5 OVERDOSAGE

No data are available with regard to human overdosage by accidental or deliberate ingestion of

dorzolamide and timolol.

There have been reports of inadvertent overdose with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most common signs and symptoms to be expected with overdose of dorzolamide are electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects (see [8 ADVERSE REACTIONS](#)).

Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyze readily.

Specific therapeutic measures for the treatment of overdose with timolol maleate are listed below for ease of reference.

**Gastric lavage:** If ingested.

**Symptomatic bradycardia:** Use atropine sulfate intravenously in a dosage of 0.25 to 2 mg to induce vagal blockade. If bradycardia persists, intravenous isoproterenol hydrochloride should be administered cautiously. In refractory cases, the use of a transvenous cardiac pacemaker may be considered.

**Hypotension:** Use sympathomimetic pressor drug therapy, such as dopamine, dobutamine or levarterenol. In refractory cases, the use of glucagon hydrochloride has been reported to be useful.

**Bronchospasm:** Use isoproterenol hydrochloride. Additional therapy with aminophylline may be considered.

**Acute cardiac failure:** Conventional therapy with digitalis, diuretics and oxygen should be instituted immediately. In refractory cases, the use of intravenous aminophylline is suggested. If necessary, this may be followed by glucagon hydrochloride which has been reported to be useful.

**Heart block (second or third degree):** Use isoproterenol hydrochloride or a transvenous cardiac pacemaker.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form/ Strength/Composition	Non-medicinal Ingredients
Ophthalmic	Solution, each mL contains dorzolamide 20 mg and timolol 5 mg	Hydroxyethyl cellulose Mannitol Sodium citrate dihydrate Sodium hydroxide solution Water for injection Benzalkonium chloride (0.0075%) is added as a preservative.

M-DORZOLAMIDE-TIMOLOL sterile ophthalmic solution is slightly opalescent, colourless-to nearly colourless, isotonic, buffered, slightly viscous, aqueous solution. Each milliliter of M-DORZOLAMIDE-TIMOLOL contains 20 mg dorzolamide (22.3 mg of dorzolamide hydrochloride) and 5 mg timolol (6.83 mg of timolol maleate) as the active ingredients.

M-DORZOLAMIDE-TIMOLOL (dorzolamide and timolol) is supplied in translucent, low-density polyethylene ophthalmic dispensers with a screw cap and dropper. Tamper evidence is provided on the container label.

M-DORZOLAMIDE-TIMOLOL is available in 10 mL dispensers (fill volumes of 5 mL per 10 mL bottle; and 10 mL per 10 mL bottle).

## 7 WARNINGS AND PRECAUTIONS

### General

As with other topically-applied ophthalmic agents, the active substances may be absorbed systemically. Dorzolamide is a sulfonamide and timolol is a beta-blocker. Therefore, the same types of adverse reactions found with systemic administration of sulfonamides or beta-blockers may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

If signs of serious reactions or hypersensitivity occur, discontinue use of this preparation.

The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide and timolol has not been studied in patients with acute angle-closure glaucoma.

### Carcinogenesis and Mutagenesis

#### Carcinogenicity

##### *Dorzolamide Hydrochloride*

The results of studies of dorzolamide hydrochloride administered orally to male and female

Sprague-Dawley rats have shown that urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day and no treatment-related tumors were seen in female and male mice given oral doses up to 75 mg/kg/day.

### ***Timolol Maleate***

The results of studies of timolol maleate in rats have shown an increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day and increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinoma in female mice at 500 mg/kg/day.

See [16 NON-CLINICAL TOXICOLOGY](#).

### **Mutagenicity**

#### ***Dorzolamide Hydrochloride***

Dorzolamide hydrochloride was devoid of mutagenic potential in the conducted evaluations.

#### ***Timolol Maleate***

Timolol Maleate was devoid of mutagenic potential in the conducted evaluations.

See [16 NON-CLINICAL TOXICOLOGY](#).

### **Cardiovascular**

Because of the timolol maleate component, cardiac failure should be adequately controlled before beginning therapy with M-DORZOLAMIDE-TIMOLOL (dorzolamide and timolol).

Patients with a history of cardiac disease, including cardiac failure, should be watched for signs of deterioration of these diseases, and pulse rates should be checked.

Due to its negative effect on conduction time, beta blockers should be given with caution to patients with first degree heart block.

Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and rarely death in association with cardiac failure, have been reported following administration of timolol maleate ophthalmic solution.

Patients with severe peripheral circulatory disturbance/disorders (e.g., severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

### **Contamination**

To minimize the contamination potential, patients should not touch the eye, the area around the eye, or any other surface with the tip of the container. It may become contaminated with bacteria. This can cause eye infections. This could lead to serious damage of the eye including loss of vision. Keep the tip of the container away from contact with any surface.

### **Driving and Operating Machinery**

Due caution should be exercised when driving or operating a vehicle or potentially dangerous machinery.



## **Endocrine and Metabolism**

### ***Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus***

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycemia.

### ***Masking of Thyrotoxicosis***

Beta-adrenergic blocking agents may mask certain clinical signs of hyperthyroidism (e.g., tachycardia). Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a thyroid storm.

## **Hepatic/Biliary/Pancreatic**

Dorzolamide and timolol has not been studied in patients with hepatic impairment and therefore should be used with caution in such patients.

## **Immune**

### ***Immunology and Hypersensitivity***

In clinical studies, local ocular adverse effects, primarily conjunctivitis and eyelid reactions, were reported with chronic administration of dorzolamide hydrochloride ophthalmic solution. Some of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. Similar reactions have been reported with dorzolamide and timolol. If such reactions are observed, discontinuation of treatment with M-DORZOLAMIDE-TIMOLOL should be considered.

While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to accidental, diagnostic, or therapeutic repeated challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions.

## **Monitoring and Laboratory Tests**

Dorzolamide and timolol was not associated with clinically meaningful electrolyte disturbances.

## **Neurologic**

### ***Muscle Weakness***

Beta-adrenergic blockade has been reported to increase muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenic symptoms.

### ***Cerebrovascular Insufficiency***

Because of potential effects of beta-adrenergic blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of

therapy with M-DORZOLAMIDE-TIMOLOL, alternative therapy should be considered.

## **Ophthalmologic**

### ***Corneal Edema***

There is an increased risk of developing irreversible corneal edema in a subset of glaucoma patients with endothelial abnormalities including cellular density and/or morphology. In this group of patients, evaluation of the cornea, with particular attention to the corneal endothelium, is recommended prior to and during treatment with M-DORZOLAMIDE-TIMOLOL.

### ***Corneal Edema and Irreversible Corneal Decompensation***

Corneal edema and irreversible corneal decompensation have been reported in patients with pre-existing chronic corneal defects and/or a history of intraocular surgery while using dorzolamide. M-DORZOLAMIDE-TIMOLOL should be used with caution in such patients.

### ***Contact Lenses***

M-DORZOLAMIDE-TIMOLOL contains the preservative benzalkonium chloride, which may be deposited in soft contact lenses; therefore, M-DORZOLAMIDE-TIMOLOL should not be administered while wearing these lenses. The lenses should be removed before application of the drops and not be reinserted earlier than 15 minutes after use.

### ***Choroidal Detachment***

Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g., timolol, acetazolamide) after filtration procedures. Management of eyes with chronic or recurrent choroidal detachment should include stopping all forms of aqueous suppressant therapy and treating endogenous inflammation vigorously.

## **Peri-Operative Considerations**

### ***Surgical Anesthesia***

The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. If necessary, during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levarterenol (see [5 OVERDOSAGE](#)).

### ***Respiratory***

In patients with mild/moderate chronic obstructive pulmonary disease (COPD), M-DORZOLAMIDE-TIMOLOL should be used with caution, and only if the potential benefit outweighs the potential risk.

## **7.1 Special Populations**

### **7.1.1 Pregnant Women**

There are no adequate and well-controlled studies in pregnant women. M-DORZOLAMIDE-TIMOLOL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### 7.1.2 Breast-feeding

It is not known whether dorzolamide hydrochloride is excreted in human milk. Timolol maleate does appear in human milk. Because of the potential for serious adverse reactions on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

In a study of dorzolamide hydrochloride in lactating rats, decreases in body weight gain of 5 to 7% in offspring at an oral dose of 7.5 mg/kg/day (94 times the maximum recommended human ophthalmic dose) were seen during lactation. A slight delay in postnatal development (incisor eruption, vaginal canalization and eye openings), secondary to lower fetal body weight, was noted at 7.5 mg/kg/day (94 times the maximum recommended human ophthalmic dose).

### 7.1.3 Pediatrics

**Pediatrics (<18 years of age):** No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

### 7.1.4 Geriatrics

**Geriatrics (>65 years of age):** Of the total number of patients in clinical studies of dorzolamide and timolol eye drops, 49% were 65 years of age and over, while 13% were 75 years of age and over.

No overall differences in effectiveness or safety were observed between these patients and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

Adverse reactions have been seen with dorzolamide hydrochloride and timolol maleate, thus potential adverse reactions following the use of M-DORZOLAMIDE-TIMOLOL may include:

#### **Dorzolamide Hydrochloride**

Headache; eyelid inflammation; eyelid crusting; eyelid irritation; asthenia/fatigue; iridocyclitis; rash; dizziness; paresthesia; superficial punctate keratitis, transient myopia (which resolved upon discontinuation of therapy); signs and symptoms of local reactions including palpebral reactions and systemic allergic reactions including angioedema, bronchospasm, urticaria, epistaxis and pruritus; throat irritation, dry mouth.

#### **Timolol Maleate (topical formulation)**

Signs and symptoms of ocular irritation, including conjunctivitis, blepharitis, keratitis, and decreased corneal sensitivity, dry eyes; visual disturbances, including refractive changes (due to withdrawal of miotic therapy in some cases), diplopia, and ptosis; choroidal detachment following filtration surgery, tinnitus; aggravation or precipitation of certain cardiovascular pulmonary and other disorders presumably related to effects of systemic beta-blockade has

been reported (see [2 CONTRAINDICATIONS](#), [7 WARNINGS AND PRECAUTIONS](#)). These include bradycardia; arrhythmia; hypotension; syncope; heart block; cerebrovascular accident; cerebral ischemia; palpitation; cardiac arrest, edema, claudication, Raynaud's phenomenon, cold hands and feet; congestive heart failure, and in insulin-dependent diabetics, masked symptoms of hypoglycemia have been reported rarely. In clinical trials, slight reduction of the resting heart rate in some patients; bronchospasm (predominantly in patients with pre-existing bronchospastic disease); cough; headache; asthenia; fatigue; chest pain; alopecia; psoriasiform rash or exacerbation of psoriasis; signs and symptoms of allergic reactions including anaphylaxis angioedema, urticaria, localized and generalized rash; dizziness; increase in signs and symptoms of myasthenia gravis; insomnia; nightmares; memory loss; paresthesia; diarrhea, dyspepsia, dry mouth; abdominal pain; decreased libido, Peyronie's disease; sexual dysfunction; systemic lupus erythematosus; myalgia.

### **Timolol Maleate (systemic formulation)**

Adverse reactions reported in clinical experience with oral timolol maleate may be considered potential side effects of ophthalmic timolol maleate.

## **8.2 Clinical Trial Adverse Reactions**

Clinical trials are conducted under very specific conditions. Therefore, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

In clinical studies, no adverse reactions specific to this combination drug have been observed. Adverse reactions have been limited to those that were reported previously with dorzolamide hydrochloride and/or timolol maleate. In general, common adverse reactions were mild and did not cause discontinuation.

During clinical studies of up to 15 months duration, 1035 patients were treated with dorzolamide and timolol. Approximately 2.4% of all patients discontinued therapy with dorzolamide and timolol because of local ocular adverse reactions. Approximately 1.2% of all patients discontinued use because of local adverse reactions suggestive of allergy or hypersensitivity.

The most frequently reported drug-related adverse reactions were: ocular burning and stinging (10.7%), taste perversion (5.8%), corneal erosion (2.0%), conjunctival injection (1.8%), blurred vision (1.4%), tearing (1.0%), and ocular itching. Urolithiasis was reported rarely (0.9%).

## **8.5 Post-Market Adverse Reactions**

The following adverse reactions have been reported in post-marketing experience: dyspnea, respiratory failure, contact dermatitis, bradycardia, heart block, choroidal detachment following filtration surgery, nausea, corneal edema in glaucoma patients with endothelial abnormalities including cellular density and/or morphology, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

## 9 DRUG INTERACTIONS

### 9.2 Drug Interactions Overview

Specific drug interaction studies have not been performed with dorzolamide and timolol.

In clinical studies, dorzolamide and timolol was used concomitantly with the following systemic medications without evidence of adverse interactions: ACE-inhibitors, calcium channel blockers, diuretics, non-steroidal anti-inflammatory drugs including acetylsalicylic acid, and hormones (e.g., estrogen, insulin, thyroxine). However, the potential for interactions with any drug should be considered.

### 9.4 Drug-Drug Interactions

The drugs listed below are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

The following drug interactions have been associated either with the components of M-DORZOLAMIDE-TIMOLOL or with other beta-blockers or sulfonamides.

**Acid-base Disturbances:** The dorzolamide component of M-DORZOLAMIDE-TIMOLOL is a carbonic anhydrase inhibitor and, although administered topically, it is absorbed systemically. In clinical studies, dorzolamide hydrochloride ophthalmic solution was not associated with acid-base disturbances. However, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving M-DORZOLAMIDE-TIMOLOL.

**Calcium Channel Blockers or Catecholamine-depleting Drugs:** The potential exists for additive effects and production of hypotension, atrioventricular conduction disturbances, left ventricular failure and/or marked bradycardia when timolol maleate ophthalmic solution is administered together with oral calcium channel blockers, catecholamine-depleting drugs antiarrhythmics, parasymphomimetics, or beta-adrenergic blocking agents.

**Quinidine:** Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.

**Clonidine:** Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are co-administered, the beta-adrenergic blocking agent should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-adrenergic blocking agents should be delayed for several days after clonidine administration has stopped.

**Beta-adrenergic Blockers:** Patients who are already receiving a beta-adrenergic blocking agent systemically and who are given M-DORZOLAMIDE-TIMOLOL should be observed for a potential additive effect either on the IOP or on the known systemic effects of beta-blockade. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.

**Epinephrine:** Although M-DORZOLAMIDE-TIMOLOL used alone has little or no effect on pupil size, mydriasis resulting from concomitant use of timolol maleate and epinephrine has been reported occasionally.

### **9.5 Drug-Food Interactions**

Interactions with food have not been established.

### **9.6 Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **9.7 Drug-Laboratory Test Interactions**

Clinically important changes in standard laboratory parameters were rarely associated with the administration of systemic timolol maleate. Slight increases in blood urea nitrogen, serum potassium, serum uric acid and triglycerides, and slight decreases in hemoglobin, hematocrit and HDL-cholesterol occurred, but were not progressive or associated with clinical manifestations.

## **10 CLINICAL PHARMACOLOGY**

### **10.1 Mechanism of Action**

Dorzolamide and timolol is the first ophthalmic combination of dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated IOP by reducing aqueous humor secretion, but does so by a different mechanism of action.

Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II (CA-II). Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a nonselective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents results in additional IOP reduction compared to either component administered alone.

Following topical administration, dorzolamide and timolol reduces elevated IOP, whether or not associated with glaucoma. Elevated IOP is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. Dorzolamide and timolol reduces IOP without the common side effects of miotics such as night blindness, accommodative spasm and pupillary constriction.

### **10.3 Pharmacokinetics**

#### **Dorzolamide Hydrochloride Absorption:**

Unlike oral carbonic anhydrase inhibitors, topically-applied dorzolamide hydrochloride exerts its effects at substantially low doses and therefore with less systemic exposure. When applied

topically, dorzolamide reaches the systemic circulation.

**Distribution:**

To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in red blood cells (RBCs) and plasma, and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free drug in plasma are maintained.

**Metabolism:**

The parent drug forms a single N-desethyl metabolite that inhibits CA-II less potently than the parent drug but also inhibits a less active isoenzyme (carbonic anhydrase I (CA-I)). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%).

**Elimination:**

Dorzolamide is excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs in a non-linear manner, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.

To simulate the maximum systemic exposure after long term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 4 mg/day closely approximates the maximum amount of dorzolamide delivered by topical ocular administration of dorzolamide hydrochloride 2% t.i.d. (ter in die (three times a day)) Dorzolamide and metabolite reached steady state by 4 and 13 weeks, respectively, and the following observations were noted:

- In plasma, concentrations of dorzolamide and metabolite were generally below the assay limit of quantitation (15 nM) indicating almost no free drug or metabolite;
- In RBCs, dorzolamide concentrations approached the binding capacity of CA-II (20–25 mcM) and metabolite concentrations approached 12–15 mcM, well below the binding capacity of CA-I (125–155 mcM);
- In RBCs, inhibition of CA-II activity and total carbonic anhydrase activity was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration.

**Timolol Maleate Absorption:**

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily topical administration of timolol maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.

By comparison to plasma concentration (10 to 20 ng/mL) following oral 5 mg dose, it was estimated that timolol was approximately 50% bioavailable systemically following intraocular

administration.

**Distribution:**

Timolol maleate combines reversibly with a part of the cell membrane, the beta-adrenergic receptor, and thus inhibits the usual biologic response that would occur with stimulation of that receptor. This specific competitive antagonism blocks stimulation of the beta-adrenergic receptors by catecholamines having beta-adrenergic stimulating (agonist) activity, whether these originate from an endogenous or exogenous source. Reversal of this blockade can be accomplished by increasing the concentration of the agonist, which will restore the usual biologic response.

**Metabolism:**

Timolol maleate (S(-) enantiomer) is significantly metabolized after oral and ophthalmic administration. Based on correlation with debrisoquine metabolism, timolol metabolism is mediated primarily by cytochrome P-450 2D6. Dorzolamide is eliminated primarily by urinary excretion as unchanged drug. The metabolic pathway utilized by dorzolamide (cytochrome P-450 2C9, 2C19, and 3A4) is different from that utilized by timolol. *In vitro* studies using human liver microsomes have shown that dorzolamide at concentrations up to 200 mcM does not affect the metabolism of timolol. Therefore, there is little potential for altered systemic exposure to either drug when administered in combination. Timolol is moderately (< 60%) bound to plasma proteins.

**Elimination:**

The drug and the metabolites (hydroxyethylamino, hydroxyethylglycolamino derivatives and a third minor metabolite that results from the hydroxylation of a terminal methyl group on the tertiary butylamino moiety) are excreted primarily via the kidney.

**11 STORAGE, STABILITY AND DISPOSAL**

Store at 15-30°C Protect from light.

Keep out of sight and reach of children.

**12 SPECIAL HANDLING INSTRUCTIONS**

Keep the tip of the container away from the eye, area around the eye, or contact with any surface.

See [4.1 Dosing Considerations](#), [4.4 Administration](#), [7 WARNINGS AND PRECAUTIONS, Contamination](#) and [7 WARNINGS AND PRECAUTIONS, Contact Lenses](#).



## PART II: SCIENTIFIC INFORMATION

### 13 PHARMACEUTICAL INFORMATION

#### Drug Substance

M-DORZOLAMIDE-TIMOLOL contains dorzolamide hydrochloride and timolol maleate.


#### Dorzolamide Hydrochloride

Proper name: dorzolamide hydrochloride

Chemical name: (4*S-trans*)-4-(Ethylamino)-5,6-dihydro-6-methyl-4*H*-thieno[2,3- *b*]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride is optically active.

Molecular formula and molecular mass: C<sub>10</sub>H<sub>16</sub>N<sub>2</sub>O<sub>4</sub>S<sub>3</sub>.HCl, 360.91 g/mol

Structural formula:



Physicochemical properties: Dorzolamide hydrochloride is a white to off-white, free flowing crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol and has a melting point of about 264 °C. The specific rotation is  $\alpha_{D}^{25} (C = 1, \text{water}) = \sim -17^\circ$ .


#### Timolol Maleate

Proper name: timolol maleate

Chemical name: (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-2-propanol(Z)-2-butenedioate(1:1) (salt) active.

Molecular formula and molecular mass: C<sub>13</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S.C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>, 432.50 g/mol

Structural formula:



Physicochemical properties: Timolol maleate is a beta-adrenergic receptor blocking agent. It possesses an asymmetric carbon atom in its structure and is provided as the levo isomer. It is a white odourless, crystalline powder which is soluble in water, methanol and alcohol. It has a melting point of 201.5 °C to 202.5°C.

## 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

#### Elevated Intraocular Pressure

**Table 2 – Summary of patient demographics for clinical trials in the treatment of elevated intraocular pressure (IOP)**

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Study 1	3-month, parallel, randomized, double-masked, active-controlled, multicenter study	2% dorzolamide/0.5 % timolol solution (dorzolamide and timolol) ophthalmic <i>bid</i> , 3 months 2% dorzolamide solution and 0.5% timolol solution (concomitant group) ophthalmic <i>bid</i> , 3 months	299	63.1 years old (23–84)	M: 113 F: 186
Study 2	3-month, parallel, randomized, double-masked, active-controlled, multicenter clinical trial	2% dorzolamide/0.5 % timolol solution (dorzolamide and timolol) ophthalmic <i>bid</i> , 3 months 2% dorzolamide solution ophthalmic <i>tid</i> , 3 months 0.5% timolol solution ophthalmic <i>bid</i> , 3 months	335	62.0 years old (27-84)	M: 171 F: 164

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex
Study 3	3-month, parallel, randomized, double-masked, active-controlled multicenter study	2% dorzolamide/0.5 % timolol solution (dorzolamide and timolol) ophthalmic <i>bid</i> , 3 months 2% dorzolamide solution ophthalmic <i>tid</i> , 3 months 0.5% timolol solution ophthalmic <i>bid</i> , 3 months	253	63.7 years old (28-88)	M: 111 F: 142
Study 4	3-month, multicenter, parallel, randomized, double-masked clinical trial with 9 months open label extension	2% dorzolamide/0.5 % timolol solution (dorzolamide and timolol) ophthalmic <i>bid</i> 2% dorzolamide solution and 0.5% timolol solution (concomitant group) ophthalmic <i>bid</i>	242	61.2 years old (22 to 84)	M: 121 F: 121

Clinical studies (Studies 1 – 4) of up to 15 months duration were conducted to compare the IOP-lowering effect of dorzolamide and timolol *bid* (dosed morning and bedtime) to individually and concomitantly administered 0.5% timolol and 2% dorzolamide in patients with glaucoma or ocular hypertension for whom concomitant therapy is appropriate. This includes both untreated patients and patients inadequately controlled with timolol monotherapy. The IOP-lowering effect of dorzolamide and timolol *bid* was greater than that of monotherapy with either 2% dorzolamide *tid* or 0.5% timolol *bid*. The IOP-lowering effect of dorzolamide and timolol *bid* was equivalent to that of concomitant therapy with dorzolamide *bid* and timolol *bid*.

**Comparison to Concomitant Therapy (Patients initiated on timolol therapy)**

In a 3-month randomized, double-masked, parallel clinical study, patients receiving dorzolamide and timolol *bid* (n = 151) were compared to patients receiving 0.5% timolol *bid* plus 2%

dorzolamide *bid* concomitantly (n = 148). At morning trough (hour 0) and morning peak (hour 2), patients receiving dorzolamide and timolol experienced IOP-lowering that was equivalent to that seen in the patients receiving the individual components concomitantly. Reductions in IOP were observed relative to the baseline value obtained after 2 weeks of 0.5% timolol *bid* monotherapy (Study 1, Table 3).

**Table 3 - Results of study 1 in the treatment of elevated intraocular pressure (IOP)**

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for active control <sup>a</sup>
Additional mean reduction in IOP from timolol baseline (mmHg) <sup>b</sup> [mean % reduction in IOP]	Day 90 (hour 0): 4.2 [16.3%] Day 90 (hour 2): 5.4 [21.6%]	Day 90 (hour 0): 4.2 [16.3%], p>0.05 vs. dorzolamide and timolol Day 90 (hour 2): 5.4 [21.8%], p>0.05 vs. dorzolamide and timolol
a. Active control: 0.5% timolol <i>bid</i> + 2% dorzolamide <i>bid</i>		
b. Patients were required to have baseline IOP ≥ 22 mmHg for enrollment.		

**Comparison to Monotherapy (Patients washed out from previous therapy)**

A 3-month randomized, double-masked parallel clinical study compared dorzolamide and timolol *bid* (n = 114) to 0.5% timolol *bid* monotherapy (n = 112) and 2% dorzolamide *tid* monotherapy (n = 109) in patients for whom concomitant therapy was appropriate. After a 3-week washout of all previous ocular hypotensive therapies, those patients receiving dorzolamide and timolol experienced IOP - lowering at both morning trough (hour 0) and morning peak (hour 2) that was greater than that seen in patients receiving either component alone (Study 2, Table 4).

**Table 4 - Results of study 2 in the treatment of elevated intraocular pressure (IOP)**

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for active control <sup>a</sup>
Additional mean reduction in IOP from baseline (mmHg) <sup>b</sup> [mean % reduction in IOP]	Day 90 (hour 0): 7.7 [27.4%] Day 90 (hour 2): 9.0 [32.7%]	2% dorzolamide <i>tid</i> : Day 90 (hour 0): 4.6 [15.5%], p<0.001 vs. dorzolamide and timolol

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for active control <sup>a</sup>
		Day 90 (hour 2): 5.4 [19.8%], p<0.001 vs. dorzolamide and timolol 0.5% timolol <i>bid</i> : Day 90 (hour 0): 6.4 [22.2%], p=0.003 vs. dorzolamide and timolol Day 90 (hour 2): 6.3 [22.6%], p<0.001 vs. dorzolamide and timolol
a. Active controls: 0.5% timolol <i>bid</i> or 2% dorzolamide <i>tid</i> b. Patients were required to have baseline IOP ≥ 24 mmHg for enrollment.		

**Comparison to Monotherapy (Patients initiated on timolol therapy)**

In a 3-month randomized, double-masked parallel clinical study in patients with elevated IOP inadequately controlled after 3 weeks of 0.5% timolol *bid* monotherapy, patients receiving dorzolamide and timolol *bid* (n = 104) experienced IOP-lowering at both morning trough (hour 0) and morning peak (hour 2) that was greater than that seen in patients receiving either 0.5% timolol *bid* monotherapy (n = 98) or 2% dorzolamide *tid* monotherapy (n = 51) (Study 3, Table 5).

**Table 5 - Results of study 3 in the treatment of elevated intraocular pressure (IOP)**

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for active control <sup>a</sup>
Additional mean reduction in IOP from timolol baseline (mmHg) <sup>b</sup> [mean % reduction in IOP]	Day 90 (hour 0): 2.8 [10.6%] Day 90 (hour 2): 4.4 [17.3%]	2% dorzolamide <i>tid</i> : Day 90 (hour 0): 1.4 [4.9%], Treatment Difference: -5.63 95% CI: (-10.15 to -1.12) Day 90 (hour 2): 2.0 [7.4%], Treatment Difference: -9.71 95% CI: (-14.78 to -4.64) 0.5% timolol <i>bid</i> : Day 90 (hour 0): 1.7 [6.7%], Treatment Difference: -3.91 95% CI: (-7.63 to -0.19) Day 90 (hour 2): 1.6 [6.6%], Treatment Difference: -11.13 95% CI: (-15.35 to -6.90)
<p>a. Active controls: 0.5% timolol <i>bid</i> or 2% dorzolamide <i>tid</i></p> <p>b. Patients were required to have baseline IOP ≥ 22 mmHg for enrollment.</p>		

**Long-term Studies**

Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP-lowering effect of dorzolamide and timolol *bid* was demonstrated throughout the day and this effect was maintained during long-term administration (Study 4, Table 6).

**Table 6 - Results of study 4 in the treatment of elevated intraocular pressure (IOP)**

Primary Endpoints	Associated value and statistical significance for Drug at specific dosages	Associated value and statistical significance for active control <sup>a</sup>
Additional mean reduction in IOP from timolol baseline (mmHg) <sup>b</sup> [mean % reduction in IOP]	Day 90 (hour 0): 3.6 [13.8%] Day 90 (hour 2): 5.0 [19.7%] Day 90 (hour 8): 3.7 [14.9%] Month 12 (hour 0): 3.5 [13.7%] Month 12 (hour 2): 5.1 [20.5%]	Day 90 (hour 0): 4.1 [15.5%], p=0.99 vs. dorzolamide and timolol Day 90 (hour 2): 4.9 [19.1%], p=0.997 vs. dorzolamide and timolol Day 90 (hour 8): 4.3 [17.4%], P=0.967 vs. dorzolamide and timolol Month 12 (hour 0): 3.2 [12.1%] Month 12 (hour 2): 5.0 [20.0%]
<p>a. Active control: 0.5% timolol <i>bid</i> and 2% dorzolamide <i>tid</i></p> <p>b. Patients were required to have baseline IOP ≥ 22 mmHg for enrollment.</p>		

## 15 MICROBIOLOGY

M-DORZOLAMIDE-TIMOLOL contains the preservative benzalkonium chloride as an antimicrobial preservative.

## 16 NON-CLINICAL TOXICOLOGY

### General Toxicology:

#### Acute Toxicity

The oral LD<sub>50</sub> of dorzolamide hydrochloride is 1320 mg/kg (3960 mg/m<sup>2</sup>) in male and female mice and 1927 mg/kg (11,369 mg/m<sup>2</sup>) in female rats.

The oral LD<sub>50</sub> of timolol maleate is 1190 mg/kg (3570 mg/m<sup>2</sup>) in female mice and 900 mg/kg (5310 mg/m<sup>2</sup>) in female rats.

#### Chronic Toxicology

##### Dorzolamide Hydrochloride and Timolol Maleate

No adverse ocular effects were seen in rabbits and dogs treated topically with dorzolamide hydrochloride and timolol maleate ophthalmic solution in studies lasting 3 and 6 months, respectively.

No adverse ocular effects were seen in monkeys and rabbits treated topically with 2% dorzolamide hydrochloride and 0.5% timolol maleate ophthalmic solutions administered concomitantly in studies lasting 15 days and 1 month, respectively.

## **Timolol Maleate**

No adverse ocular effects were observed in rabbits and dogs administered timolol maleate ophthalmic solution topically in studies lasting 1 and 2 years, respectively.

## **Dorzolamide Hydrochloride**

In repeated oral dose toxicity studies of dorzolamide hydrochloride in rodents, dogs and monkeys, the following effects were noted:

- An increased incidence of urothelial hyperplasia was noted in rats and mice. This is a class-effect of carbonic anhydrase inhibitors (CAIs) specific to rodents and is secondary to increased urinary sodium, potassium, pH, and crystals.
- Another class effect of CAIs seen only in rodents was renal papillary cytoplasmic granularity associated with potassium depletion in the kidney. No-effect levels for these microscopic changes were not observed. However, these findings are rodent specific and not seen in monkeys at oral doses up to 50 mg/kg/day (625 times the maximum recommended human ophthalmic dose).
- Metabolic acidosis and the related gastric mucous neck cell hyperplasia were seen in dogs and monkeys. In dogs, the gastric change was seen at a dose as low as 0.2 mg/kg/day in a one-month study, but disappeared with continued dosing and was absent at one year at a dose as high as 2 mg/kg/day. In monkeys, in a one-month study, the gastric change was seen at a dose of 50 mg/kg/day orally, but no effects were seen at 10 mg/kg/day orally, or when 0.4 mg/kg/day (~5 times the maximum recommended human ophthalmic dose) was applied topically to the eye for 1 year.
- Another high dose phenomenon observed in dogs and monkeys (doses  $\geq$  1.5 mg/kg/day and 50 mg/kg/day, respectively) in short term studies was decreased remodeling of bone, probably as a result of inhibition of carbonic anhydrase in osteoclasts. Longer term studies in dogs showed the change was transient.
- Marginal non-progressive decreases in some erythroid parameters were seen in dogs and monkeys at dorzolamide plasma levels of 50 ng/mL in dogs and 1660 ng/mL in monkeys. The plasma levels of dorzolamide in humans given the maximum recommended ophthalmic dose are generally  $\leq$  5 ng/mL.

## **Carcinogenicity:**

### **Dorzolamide Hydrochloride**

In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the maximum recommended human ophthalmic dose).

Papillomas were not seen in rats given oral doses equivalent to approximately twelve times the maximum recommended human ophthalmic dose. No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day (~900 times the maximum recommended human ophthalmic dose).



The increased incidence of urinary bladder papillomas seen in the high-dose male rats is a class-effect of CAIs in rats and is secondary to increased urinary sodium, potassium, pH and crystals, all changes induced by CAIs. Rats are particularly prone to developing papillomas in response to foreign bodies, compounds causing crystalluria and sodium salts of diverse compounds that are inert when given as calcium salts.

No changes in bladder urothelium were seen in dogs given oral dorzolamide for one year at 2 mg/kg/day or in monkeys given oral dorzolamide for one month at 50 mg/kg/day (the urothelial changes in the bladder occurred with oral dosing in rats within one month). In addition, monkeys dosed topically to the eye with 0.4 mg/kg/day (~5 times the maximum recommended human ophthalmic dose) for 1 year had no urothelial changes in the bladder.

### **Timolol Maleate**

In a 2-year oral study of timolol maleate in rats, there was a statistically significant ( $p \leq 0.05$ ) increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day (300 times the maximum recommended human oral dose of 60 mg of timolol, as one drop of timolol maleate 0.5% ophthalmic solution contains about 0.2 mg of timolol).

Similar differences were not observed in rats administered oral doses equivalent to 25 or 100 times the maximum recommended human oral dose.

In a lifetime oral study in mice, there were statistically significant ( $p \leq 0.05$ ) increases in the incidence of benign and malignant pulmonary tumors, benign uterine polyps and mammary adenocarcinoma in female mice at 500 mg/kg/day (500 times the maximum recommended human dose), but not at 5 or 50 mg/kg/day. In a subsequent study in female mice, in which post-mortem examinations were limited to uterus and lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.

The increased occurrence of mammary adenocarcinoma was associated with elevations in serum prolactin which occurred in female mice administered timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents which elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in man. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate, the maximum recommended human oral dosage, there were no clinically meaningful changes in serum prolactin.

### **Genotoxicity:**

#### **Dorzolamide Hydrochloride**

Dorzolamide hydrochloride was devoid of mutagenic potential when evaluated in the following 5 tests: (1) in vivo (mouse) in the cytogenetic assay at doses up to 500 mg/kg/day (6250 times the maximum recommended human ophthalmic dose); (2) in vitro in the chromosomal aberration assay; (3) in the alkaline elution assay; (4) in the V-79 assay (doses up to 10 mcM); and (5) in the Ames test, in which the highest concentration of dorzolamide hydrochloride used, 10,000 mcg/plate, did not result in a two-fold or greater increase in revertants with tester strains of *S. typhimurium* and *E. coli*.

## **Timolol Maleate**

Timolol maleate was devoid of mutagenic potential when evaluated *in vivo* (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and *in vitro* in a neoplastic cell transformation assay (up to 100 mcg/mL). Using the Ames test, the highest concentrations of timolol employed, 5000 or 10,000 mcg/plate, were associated with statistically significant elevations ( $p \leq 0.05$ ) of revertants observed with tester strain TA 100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA 100, no consistent dose-response relationship was observed, nor did the ratio of test to control revertants reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.

## **Reproductive and Developmental Toxicology:**

### **Dorzolamide Hydrochloride**

In reproduction studies of dorzolamide hydrochloride in rats, there were no adverse effects on males or females at doses up to 188 or 94 times, respectively, the maximum recommended human ophthalmic dose.

There were no treatment-related fetal malformations in developmental toxicity studies with dorzolamide hydrochloride in rats at oral doses up to 10 mg/kg/day (125 times the maximum recommended human ophthalmic dose). Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of  $\geq 2.5$  mg/kg/day (31 times the maximum recommended human ophthalmic dose) revealed malformations of the vertebral bodies.

These malformations occurred only at doses that caused metabolic acidosis with resultant decreased body weight gain in dams and decreased fetal weights. These malformations, seen only at maternotoxic doses, appear to be a class-effect related to a combination of electrolyte and acid-base changes: decreased venous  $\text{HCO}_3^-$ , decreased venous pH and decreased serum potassium. No treatment-related malformations were seen at 1.0 mg/kg/day (13 times the maximum recommended human ophthalmic dose). Acetazolamide, an oral CAI, causes skeletal malformations in rats and rabbits by a similar mechanism.

In a study of dorzolamide hydrochloride in lactating rats, decreases in body weight gain of 5 to 7% in offspring at an oral dose of 7.5 mg/kg/day (94 times the maximum recommended human ophthalmic dose) were seen during lactation. A slight delay in postnatal development (incisor eruption, vaginal canalization and eye openings), secondary to lower fetal body weight, was noted at 7.5 mg/kg/day (94 times the maximum recommended human ophthalmic dose).

### **Timolol Maleate**

Reproduction and fertility studies in rats showed no adverse effect on male or female fertility at doses up to 150 times the maximum recommended human oral dose.

Teratogenicity studies with timolol in mice and rabbits at doses up to 50 mg/kg/day (50 times the maximum recommended human oral dose) showed no evidence of fetal malformations.

Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (1000 times the maximum recommended human oral dose) were maternotoxic in mice and resulted in an

increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 100 times the maximum recommended human oral dose, in this case without apparent maternotoxicity.

## **17 SUPPORTING PRODUCT MONOGRAPHS**

- 1 COSOPT, ophthalmic solution, 20 mg/mL dorzolamide hydrochloride and 5 mg/mL timolol maleate, submission control 259275, Product Monograph, Elvium Life Sciences (May 24, 2022).

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

#### **M-DORZOLAMIDE-TIMOLOL**

#### **Dorzolamide and Timolol Eye Drops, BP**

Read this carefully before you start taking **M-DORZOLAMIDE-TIMOLOL** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **M-DORZOLAMIDE-TIMOLOL**.

#### **What is M-DORZOLAMIDE-TIMOLOL used for?**

M-DORZOLAMIDE-TIMOLOL is used to treat high pressure in the eye in patients with the following conditions:

- Ocular hypertension
- Open-angle glaucoma

It is used along with other medicines.

#### **How does M-DORZOLAMIDE-TIMOLOL work?**

M-DORZOLAMIDE-TIMOLOL contains a combination of two medicines. One is called a carbonic anhydrase inhibiting medicine. The other is called a beta-blocking medicine. Each one works in a different way to lower the pressure in the eye.

#### **What are the ingredients in M-DORZOLAMIDE-TIMOLOL?**

Medicinal ingredients: Dorzolamide (as dorzolamide hydrochloride) and timolol (as timolol maleate)

Non-medicinal ingredients: Hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide solution, and water for injection.

Benzalkonium chloride is only added as a preservative to M-DORZOLAMIDE-TIMOLOL.

#### **M-DORZOLAMIDE-TIMOLOL comes in the following dosage forms:**

Solution: 20 mg/mL dorzolamide (as dorzolamide hydrochloride) and 5 mg/mL timolol (as timolol maleate).

#### **Do not use M-DORZOLAMIDE-TIMOLOL if you:**

- are allergic to M-DORZOLAMIDE-TIMOLOL or any of its ingredient. See “What are the ingredients in M-DORZOLAMIDE-TIMOLOL?”.
- have serious breathing problems such as asthma.
- have chronic obstructive lung disease.
- have certain heart conditions such as slow or irregular heartbeats or heart failure.

- have severe kidney problems.
- are taking medicines called carbonic anhydrase inhibitors by mouth.
- are less than 18 years of age.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take M-DORZOLAMIDE-TIMOLOL. Talk about any health conditions or problems you may have, including if you:**

- have lung or breathing problems such as chronic obstructive lung disease.
- have muscle weakness of the eye.
- have had heart problems such as heart failure in the past.
- have a heart condition called a first degree heart block.
- have an allergy to any medication.
- are pregnant or planning to become pregnant.
- are breast-feeding or planning to breast-feed.
- have or have had kidney problems.
- have or have had liver problems.
- have or have had thyroid problems.
- have or have had blood circulation problems such as Raynaud’s syndrome.
- have or have had diabetes or other blood sugar problems.
- have certain eye problems like corneal defects or have had eye surgery in the past.
- are planning to have major surgery, including eye surgery, as M-DORZOLAMIDE-TIMOLOL may change the effects of some medicines during anesthesia.

**Other warnings you should know about:**

**Contact lenses**

If you wear contact lenses, consult your doctor before using M-DORZOLAMIDE-TIMOLOL. M-DORZOLAMIDE-TIMOLOL contains the preservative benzalkonium chloride. It can deposit in soft contact lenses. This means that you must remove your contact lenses before you apply M-DORZOLAMIDE-TIMOLOL. Wait 15 minutes before putting your contact lenses back in your eyes.

**Driving and using machines**

Wait until you can see clearly before driving or operating machines after applying M-DORZOLAMIDE-TIMOLOL.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

**The following may interact with M-DORZOLAMIDE-TIMOLOL:**

- Other drugs (including eye drops) that you are using or plan to use.
- Medicines used to lower blood pressure, called calcium channel blockers or clonidine.
- Medicines used to treat heart problems such as quinidine and medicines called beta-

blockers.

- Medicines used to treat diabetes such as insulin or oral hypoglycemic agents.
- Medicines used to treat depression called selective serotonin reuptake inhibitors.
- Acetylsalicylic acid used to reduce fever and pain.
- Medicines called sulfa drugs used to treat bacterial infections.

#### **How to take M-DORZOLAMIDE-TIMOLOL:**

- Take M-DORZOLAMIDE-TIMOLOL exactly as your healthcare professional has told you to.
- If you are using M-DORZOLAMIDE-TIMOLOL with another eye drop, the drops should be applied at least 10 minutes apart.
- Be careful not to touch your eye, the area around your eye, or any other surface with the tip of the container. It may become contaminated with bacteria. This can cause eye infections. This could lead to serious damage of the eye including loss of vision. Keep the tip of the container away from contact with any surface. Contact your healthcare professional if you think the bottle might be contaminated or if you think you might have an eye infection.
- If you cannot apply M-DORZOLAMIDE-TIMOLOL to yourself a family member or caregiver may help you.
- If you are using M-DORZOLAMIDE-TIMOLOL preservative-free, the container and any remaining contents must be discarded after each application.


#### **M-DORZOLAMIDE-TIMOLOL**

1. Before using M-DORZOLAMIDE-TIMOLOL for the first time, be sure the safety seal on the front of the bottle is not broken.



**Figure A**


2. Tear off the safety seal to break the seal.



**Figure B**

3. To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will

prevent your dispenser from operating properly.



**Figure C**

4. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.



**Figure D**

5. Invert the bottle and press lightly with the thumb or index finger over the “Finger Push Area” (as shown) until a single drop is dispensed into the eye.



**Figure E**

**DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP.**

6. After application, press a finger into the corner of your eye, by the nose (as shown) for 2 minutes. This helps keep M-DORZOLAMIDE-TIMOLOL in your eye.



**Figure F**

7. If drop dispensing is difficult after you open the bottle for the first time, replace the cap on the bottle and tighten. Then, remove it by turning the cap in the opposite direction as shown by the arrows on the top of the cap.
8. Repeat steps 4, 5 and 6 with the other eye if instructed to do so by your healthcare professional.

9. Replace the cap by turning until it is firmly touching the bottle. Do not tighten the cap too much. This may damage the bottle and cap.
10. The dispenser tip is designed to provide a single drop into your eye; do not enlarge the hole of the dispenser tip.
11. After you have used all doses, there will be some M-DORZOLAMIDE-TIMOLOL left in the bottle. You should not be concerned since an extra amount of M-DORZOLAMIDE-TIMOLOL has been added to the bottle and you will still get the full amount of M-DORZOLAMIDE-TIMOLOL that your doctor prescribed. Do not attempt to remove excess medicine from the bottle.

**Usual dose:**

The usual dose is one drop in the affected eye(s) twice a day.

Your healthcare professional will tell you exactly how much M-DORZOLAMIDE-TIMOLOL you should apply and for how long you should apply it.

**Overdose:**

If you feel you have taken too much M-DORZOLAMIDE-TIMOLOL and symptoms may include shortness of breath, low heartbeat, dizziness, headache, etc., seek medical help.

If you think you, or a person you are caring for, have taken too much M-DORZOLAMIDE-TIMOLOL, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

**Missed Dose:**

It is important to apply M-DORZOLAMIDE-TIMOLOL as prescribed by your doctor. If you miss a dose, apply it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not apply a double dose.

**What are possible side effects from using M-DORZOLAMIDE-TIMOLOL?**

These are not all the possible side effects you may have when taking M-DORZOLAMIDE-TIMOLOL. If you experience any side effects not listed here, tell your healthcare professional.

Side effects may include:

- Burning, stinging, itching or redness of the eye.
- Watery eyes.
- Blurred vision.
- Swelling or crusting of the eyelids.
- Altered sense of taste including a bitter taste.
- Muscle pain.



- Abdominal pain.
- Headache.
- Nosebleed.
- Dry mouth.
- Nausea.
- Tiredness.

<b>Serious side effects and what to do about them</b>			
<b>Symptom / effect</b>	<b>Talk to your healthcare professional</b>		<b>Stop taking drug and get immediate medical help</b>
	<b>Only if severe</b>	<b>In all cases</b>	
<b>UNCOMMON</b>			
Slow heartbeat			√
<b>RARE</b>			
Heart problems: irregular heartbeat, heart block, low blood pressure.			√
Toxic Epidermal Necrolysis (severe skin reaction): redness, blistering and/or peeling of large areas of the skin.			√
Allergic Reactions: rash, hives, swelling of the mouth, throat, and lips, difficulty breathing, blue skin, shock, loss of consciousness, low blood pressure.			√
Stevens-Johnson syndrome (severe skin rash): redness, blistering and/or peeling of the skin and/or inside of the lips, eyes, mouth, nasal passages or genitals, accompanied by fever, chills, headache, cough, body aches or swollen glands.			√
Urolithiasis (kidney stones): pain when urinating, severe pain in the side and back, below the ribs.			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

### **Reporting Side Effects**

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

Store at room temperature 15°C – 30°C. Protect from light.

Keep out of reach and sight of children.

### **If you want more information about M-DORZOLAMIDE-TIMOLOL:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); or by contacting Mantra Pharma Inc. at [medinfo@mantrapharma.ca](mailto:medinfo@mantrapharma.ca) or at 1-833-248-7326.

This leaflet was prepared by

Mantra Pharma Inc.  
9150 Leduc Blvd., Suite 201  
Brossard, Quebec  
J4Y 0E3

Last Revised: MAY 09, 2023